 | • レポートコード：D0MOR-NV086 • 出版社/出版日：Mordor Intelligence / 2020年9月 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：サービス |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、リアルワールドエビデンス (RWE) ソリューションの世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、コンポーネント別（クレームデータ、臨床設定データ、患者主導データ、薬局データ、その他）分析、治療部位別（腫瘍、免疫、神経、心血管疾患、その他）分析、エンドユーザー別（医療費支払者、医療提供者、製薬・医療機器会社、その他）分析、地域別分析、競争状況、市場機会・将来分析などを整理しました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・リアルワールドエビデンス (RWE) ソリューションの世界市場規模：コンポーネント別（クレームデータ、臨床設定データ、患者主導データ、薬局データ、その他） ・リアルワールドエビデンス (RWE) ソリューションの世界市場規模：治療部位別（腫瘍、免疫、神経、心血管疾患、その他） ・リアルワールドエビデンス (RWE) ソリューションの世界市場規模：エンドユーザー別（医療費支払者、医療提供者、製薬・医療機器会社、その他） ・リアルワールドエビデンス (RWE) ソリューションの世界市場規模：地域別 ・競争状況 ・市場機会・将来分析 |
The real-world evidence solutions market will show rapid growth due to the shift from volume to value-based care, increasing aging population and prevalence of chronic diseases and delays in drug development and the subsequent increase in development costs.
Pharmaceutical companies take several years to introduce a new drug molecule to market, and they invest billions in research and development with a low probability of success. To shorten the drug development cycles, pharma research centers need a clear insight on treatment options that work in a wide population compared to few patient pools in clinical trials. The use of real-world evidence (RWE) insights is thus found increasing as pharma and biotech companies realize that RWE can be important in drug development and life-cycle management and also increase efficiency in innovation and cost of clinical trials.
The big pharmaceutical companies are found using a clinico-genomic database with tumor sequencing information for cancer discovery studies and targeted drug development. Companies are thus able to broaden their indication range and conduct a small number of clinical trials for the rare biomarker-defined population. Thus it indicates the growth of real-world evidence solutions market, during the forecast period.
In addition, the real-world data sets are widely adopted by end-users for RWE for various applications such as drug development & approvals, market access & reimbursement/coverage decisions, clinical decision-making, and medical device development & approvals, among others, that helps in the growth of the overall market.
[Key Market Trends]
Oncology is Anticipated to be the Dominant Segment During the Forecast Period
Based on the therapeutic area, the real-world evidence market is broadly categorized into oncology, immunology, neurology, cardiovascular disease, and other therapeutic areas the oncology segment has been accounted for the largest share of the real-world evidence market. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide. According to the World Health Organization (WHO), Cancer is the second leading cause of death across the globe, with an estimated 9.6 million deaths in 2018. There is also an increasing personalized medicine and a more precise requirement for oncology, which is expected to further fuel the market growth.
[North America Region Holds the Largest Market Share of Real-world Evidence Solutions Market]
North America has been accounted for the largest share of the real-world evidence market followed by Europe and the Asia Pacific. There has been a presence of a favorable regulatory environment, a high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, these factors are responsible for the major share of North America in the global real-world evidence market.
The US is expected to dominate the North American market, owing to a high demand in clinical research activities, which is one of the important factors augmenting the demand of real-world evidence solutions market in the North America region.
[Competitive Landscape]
Product launches, partnerships, collaborations, agreements, and market expansions are the key strategies adopted by players to grow and expand their presence in the real-world evidence solutions market. Some of the key players in the market includes IQVIA, ICON, PAREXEL, Oracle Corporation and Clinigen Group among others.
[Reasons to Purchase this report]
• The market estimate (ME) sheet in Excel format
• 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Shift From Volume- to Value-based Care
4.2.2 Increasing Aging Population and Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 Unwillingness to Rely on Real-world Studies
4.3.2 Lack of Standards
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Component
5.1.1 Claims Data
5.1.2 Clinical Settings Data
5.1.3 Patient-Powered Data
5.1.4 Pharmacy Data
5.1.5 Others
5.2 By Therapeutic Area
5.2.1 Oncology
5.2.2 Immunology
5.2.3 Neurology
5.2.4 Cardiovascular Disease
5.2.5 Other Therapeutic Areas
5.3 By End User
5.3.1 Healthcare Payers
5.3.2 Healthcare Providers
5.3.3 Pharmaceutical & Medical Device Companies
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Clinigen Group
6.1.2 Icon PLC
6.1.3 IBM
6.1.4 IQVIA
6.1.5 Oracle Corporation
6.1.6 Parexel International
6.1.7 PerkinElmer, Inc.
6.1.8 Pharmaceutical Product Development (PPD, Inc)
6.1.9 SAS Institute
6.1.10 Syneos Health
7 MARKET OPPORTUNITIES AND FUTURE TRENDS